Hence, CD47 serves as a target in the treatment of acute mylocytic leukemia (AML) by utilizing antibodies against CD47 to facilitate AML elimination by macrophages, which results in the blockade of inhibitory CD47–SIRPα signaling (21, 22). Here, SIRPA is linked to acute myeloid leukemia.